TX-SONAR
1.5.2024 15:01:34 CEST | Business Wire | Press release
Sonar announced today that Lynne Doherty will join the organization as President of Field Operations. In her new role, Lynne will be responsible for driving revenue, and ensuring that Sonar's customers are successful in their pursuit of Clean Code. The leading provider of Clean Code solutions, Sonar accelerates mission-critical software development, reduces technical debt, and improves code quality and code security. Lynne will lead the company’s demand generation, global sales, solutions engineering, customer success, and customer support teams globally.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240501287633/en/
Lynne Doherty joins Sonar as President of Field Operations to accelerate revenue growth and global expansion. (Photo: Business Wire)
“Lynne has an outstanding track record of leading high-performing go-to-market organizations and driving positive business outcomes. We are excited that she is joining Sonar and believe she’s the ideal leader to help us in our next phase of growth,” said Tariq Shaukat, co-CEO of Sonar. “Having started her career as a Software Developer, she has a strong understanding of the value Sonar creates and a proven track record of working with customers to achieve that value.”
Lynne brings more than 20 years of sales leadership experience to Sonar, most recently as President, of Worldwide Field Operations at Sumo Logic, where she was focused on evolving the GTM organization for operational scale and speed. This included driving customer expansion and growing new logos, shifting the segmentation model, and starting a partner-first motion. Before that, she held various leadership roles at McAfee, where she drove over a billion dollars of revenue annually. In her time at McAfee, she led the team through several business evolutions, supported McAfee’s initial public offering, and multiple acquisitions.
“Sonar is a crucial tool for software developers and engineering teams that is especially necessary for AI-assisted code. With its Clean Code methodology, Sonar addresses a significant gap in the software development lifecycle, enhancing code quality and security hand-in-hand,” said Doherty. “Joining the Sonar team feels personal for me, in a sense, as I’m getting back to my roots as a developer, where I started my career. I’m thrilled to join the Sonar team and look forward to working alongside Tariq, Olivier, and the rest of the organization to deliver Clean Code.”
Before joining McAfee, Lynne held various sales and marketing leadership roles at Cisco, where she oversaw a team of more than 2,000 employees, and drove billions in revenue annually. While at Cisco, she also played a key role in the success of acquisitions of Duo Security, Umbrella, and Cloudlock. Lynne is an independent Director on the boards of CloudBees and the American Red Cross. She holds a B.S. in Mathematics and Computer Science from Temple University.
Over the last 15 years, Sonar has analyzed more than half-a-trillion lines of code across all industries and company sizes, resulting in a deep understanding of how code is written and managed. With that knowledge, Sonar has redefined what it means to write Clean Code in today’s software development life cycle, helping organizations accelerate mission-critical software development, manage proliferating risks, and build fast and reliable applications.
Sonar is currently hiring across a number of departments. You can learn more about joining the Sonar team here.
About Sonar
Sonar is a leading developer of open source solutions to help developers write Clean Code. Sonar’s solutions — SonarQube, SonarCloud, and SonarLint — support over 30 programming languages, frameworks, and infrastructure technologies. Trusted by more than 400,000 organizations globally to clean more than half a trillion lines of code, Sonar is integral to delivering higher quality, better-performing software.
To learn more about Sonar, please visit: https://www.sonarsource.com/products/all/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240501287633/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
